<DOC>
	<DOCNO>NCT00696384</DOCNO>
	<brief_summary>The purpose study determine long term safety tolerability azilsartan medoxomil , daily ( QD ) , participant Essential Hypertension .</brief_summary>
	<brief_title>A Safety Tolerability Study Azilsartan Medoxomil Participants With Essential Hypertension</brief_title>
	<detailed_description>Hypertension affect approximately 50 million individual United States . As population age , prevalence hypertension continue increase broad effective preventive measure implement . According World Health Organization , hypertension common attributable cause preventable death develop nation , uncontrolled hypertension greatly increase risk cardiovascular disease , cerebrovascular disease , renal failure . A major component blood pressure regulation renin-angiotensin-aldosterone system , system hormone-mediated feedback interaction result relaxation constriction blood vessel response various stimulus . Angiotensin II , polypeptide hormone , form angiotensin I reaction catalyze angiotensin-converting enzyme part renin-angiotensin-aldosterone system . AII principal pressor agent renin-angiotensin-aldosterone system myriad effect cardiovascular system electrolyte homeostasis . Two receptor angiotensin II identify . Angiotensin II type 1 ( AT1 ) receptor locate predominantly vascular smooth muscle , activation angiotensin II result vasoconstriction , hypertrophic proliferation , inflammation . In contrast , stimulation angiotensin II type 2 ( AT2 ) receptor angiotensin II result vasodilation , antiproliferative effect , effect opposite AT1 receptor stimulation . Drugs modulate renin-angiotensin-aldosterone system use commonly worldwide treatment hypertension . Of , block synthesis angiotensin II inhibit angiotensin-converting enzyme inhibitor , others inhibit action angiotensin II bind directly AT1 receptor ( angiotensin II receptor blocker ) , thereby allow blood vessel dilate , result reduction blood pressure . The effect angiotensin II receptor blocker condition renin-angiotensin-aldosterone system play significant role , congestive heart failure , post-myocardial infarction management , diabetic nephropathy , also investigate . Takeda Global Research &amp; Development Center , Inc. develop TAK-491 ( azilsartan medoxomil ) treat mild moderate essential hypertension . Nonclinical study indicate azilsartan medoxomil antagonist AT1 receptor subtype . This study consist 2 phase . The first phase 26-week , open-label , multicenter phase evaluate safety tolerability TAK-491 participant essential hypertension . Investigators instruct manage participant accord protocol-specified treatment algorithm achieve target blood pressure . All participant complete open-label phase randomize 6-week double-blind , placebo-controlled ( azilsartan medoxomil [ maintain final dose open-label phase ] placebo , addition current antihypertensive medication include chlorthalidone , applicable ) reversal phase evaluate maintenance/durability azilsartan medoxomil -mediated blood pressure reduction , well potential rebound follow cessation azilsartan medoxomil . Study participation anticipate 8.5 Months . Multiple procedures occur visit may include fasting , blood collection , urine collection , vital sign include sit stand blood pressure pulse , body height weight , physical examination electrocardiograms .</detailed_description>
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Antihypertensive Agents</mesh_term>
	<mesh_term>Chlorthalidone</mesh_term>
	<criteria>Inclusion Criteria 1 . Has essential hypertension ( diastolic blood pressure ≥ 95mm Hg ≤ 119 mm Hg . For participant diabetes chronic kidney disease diastolic blood pressure must ≥ 85 mm Hg ≤ 109 mm Hg . 2 . Female participant childbearing potential ( eg , sterilize , postmenopausal ) . 3 . Female participant childbearing potential sexually active must agree use adequate contraception , neither pregnant lactating Screening throughout duration study . 4 . Clinical laboratory evaluation ( include clinical chemistry , hematology , complete urinalysis ) within reference range test laboratory unless result deem clinically significant inclusion study investigator . Exclusion Criteria 1 . Systolic blood pressure great 185 mm Hg . 2 . Is required take intend continue take disallowed medication , prescription medication , herbal treatment overthe counter medication may interfere evaluation study medication , include : 3 . Is hypersensitive AII receptor blocker . 4 . Recent history ( within last 6 month ) myocardial infarction , unstable angina , coronary artery bypass graft , percutaneous coronary intervention , cerebrovascular accident , transient ischemic attack . 5 . History moderate severe heart failure hypertensive encephalopathy . 6 . Has clinically significant cardiac conduction defect ( eg , thirddegree atrioventricular block , sick sinus syndrome ) . 7 . Has secondary hypertension etiology . 8 . Known suspected unilateral bilateral renal artery stenosis . 9 . Has severe renal dysfunction disease ( base calculate creatinine clearance &lt; 30 mL/min/1.73 m2 ) Screening .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2011</verification_date>
	<keyword>Essential Hypertension</keyword>
	<keyword>Cardiovascular Disease</keyword>
	<keyword>High Blood Pressure</keyword>
	<keyword>Drug Therapy</keyword>
</DOC>